Comparative research on the efficacy of CyberKnife® and surgical excision for Stage I hepatocellular carcinoma

• DOI: 10.2147/ott.s51452
• Publication Date: 2013-10-29T00:29:22Z
• Authors: HongQing Zhuang; qingsong pang; Yongchun Song; zhiyong yuan; Lijun Tian; Yang Dong
• Keywords: Cyberknife; Surgical excision

To retrospectively analyze and compare the outcomes of patients with hepatocellular carcinoma treated either surgical excision or CyberKnife® from September 2006 to August 2011.Local control toxicity were primary endpoints, followed by local progression-free survival, overall survival as secondary endpoints. Response Evaluation Criteria In Solid Tumors evaluation criteria for efficacy; Common Toxicity 3.0 adverse events. Local was calculated using direct method (nonactuarial). The curves drawn Kaplan-Meier along log-rank test analysis.The research included 26 tumor-free cutting edge (R0) 22 CyberKnife treatment. results showed that effects milder, 1-, 2-, 3-year rates 92.9%, 90.0%, 67.7%, respectively. treatment 88.5%, 73.1%, 69.2% same periods, while those 72.7%, 66.7%, 57.1%, this study, appeared prolong a greater extent, but no statistical significance; difference observed in tumor-specific between two cohorts.According preliminary its mild toxicity, efficacy early on par resection.